Testing effectiveness (Phase 2)Study completedNCT00526045
What this trial is testing
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
Who this might be right for
Breast CancerHematologic Neoplasms
Novartis Pharmaceuticals 117